Pacira BioSciences announced it will report its second quarter 2026 financial results on August 4, 2026, followed by a live conference call and webcast at 4:30 p.m. ET. The company is a leader in non-opioid pain therapies with three commercial-stage treatments: EXPAREL, ZILRETTA, and iovera, plus a pipeline of clinical-stage assets including PCRX-201 in Phase 2 development for osteoarthritis.

Pacira BioSciences granted inducement equity awards to ten new employees on July 2, 2026, consisting of stock options for 9,200 shares and restricted stock units for 18,200 shares. The awards were approved by the People & Compensation Committee under Nasdaq Listing Rule 5635(c)(4) without stockholder approval.

The osteoarthritis market is projected to grow at a 3% CAGR from 2026 to 2036, reaching USD 32.5 billion in 2025 across seven major markets. Growth is driven by an aging population, rising disease prevalence, and the launch of emerging therapies including LEVI-04, ZILOSUL, TissueGene-C, and AMZ001. Current treatment is dominated by opioids, but novel disease-modifying therapies and regenerative medicine approaches are expected to reshape the market landscape.

Pacira BioSciences announced inducement equity awards to ten new employees on May 4, 2026, including stock options for 36,800 shares and restricted stock units for 27,700 shares. The awards were granted under the company's Amended and Restated 2014 Inducement Plan with an exercise price of $24.69 per share.

Pacira BioSciences CFO Shawn Cross exercised and sold 12,941 shares for approximately $326,000 on April 23, 2026, representing 10.94% of his direct holdings. The transaction was part of a pre-planned Rule 10b5-1 trading plan. Despite the insider sale, the company reported strong Q1 2026 results with $177 million in revenue (5% YoY growth) and beat analyst expectations, with the stock rising about 12% in April.

Pacira BioSciences presented real-world data demonstrating that EXPAREL (bupivacaine liposome injectable suspension) is associated with lower total healthcare costs and reduced opioid utilization in outpatient total hip and knee arthroplasty procedures. Three studies showed cost savings ranging from $7,332 to $13,022 over 6 months post-surgery, with a projected cumulative cost difference of $117,868 per 1 million members by year 3 compared to ropivacaine.

Pacira BioSciences announced inducement equity awards to three new employees on March 3, 2026, including stock options for 2,400 shares and restricted stock units for 5,500 shares. The awards were granted under the company's Amended and Restated 2014 Inducement Plan with an exercise price of $22.10 per share.

The global corticosteroids market is projected to grow from USD 6.24 billion in 2025 to USD 8.45 billion by 2031 at a CAGR of 5.18%, driven by rising chronic diseases like asthma and COPD. However, safety concerns from prolonged usage and a shift toward biologics and localized therapies present significant challenges. Innovations in drug delivery systems and extended-release formulations are reshaping the market.

Pacira BioSciences received a Paragraph IV Certification Notice from Qilu Pharmaceutical regarding a generic equivalent filing for EXPAREL, challenging 18 of Pacira's patents. Pacira intends to vigorously defend its intellectual property rights.

Pacira BioSciences will present research at AMCP Nexus 2025 highlighting the clinical effectiveness and economic benefits of EXPAREL, a non-opioid pain therapy, with multiple studies focusing on pain management in knee and shoulder surgeries.

Pacira BioSciences granted inducement awards to 15 new employees, including 18,000 stock options and 32,600 restricted stock units, to incentivize new hires under their Inducement Plan.

Pacira BioSciences granted stock options and restricted stock units to nine new employees under its Inducement Plan, with 13,000 stock options and 18,100 restricted stock units awarded.